BioMarin Pharmaceutical

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders (öffnet in neuem Tab)

  Simply Wall Street · 02.10.2026

• After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. (öffnet in neuem Tab)

  Stock Titan · 01.10.2026

• BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History (öffnet in neuem Tab)

  Yahoo! Finance Canada · 01.10.2026

• The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) (öffnet in neuem Tab)

  Yahoo Finance · 01.10.2026

• BioMarin and Profluent partner on AI-designed enzyme therapies (öffnet in neuem Tab)

  Pharmaceutical Technology · 01.10.2026

• BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration (öffnet in neuem Tab)

  Simply Wall Street · 01.10.2026

• BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth (öffnet in neuem Tab)

  AD HOC NEWS · 30.09.2026

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (öffnet in neuem Tab)

  TradingView · 30.09.2026

• BioMarin Grants Ascendis Global License, Secures Royalty Revenues (öffnet in neuem Tab)

  tipranks.com · 30.09.2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (öffnet in neuem Tab)

  TradingView · 30.09.2026

• BioMarin lays off 117 California workers to consolidate footprint (öffnet in neuem Tab)

  Fierce Pharma · 30.09.2026

• Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI (öffnet in neuem Tab)

  marketscreener.com · 30.09.2026

• Profluent Partners With BioMarin to Design Novel Medicines Using AI (öffnet in neuem Tab)

  Business Wire · 30.09.2026

• Layoff Tracker: Novo, BioMarin, Enanta dole out pink slips (öffnet in neuem Tab)

  BioSpace · 30.09.2026

• BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board (öffnet in neuem Tab)

  Simply Wall Street · 26.09.2026

• BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish (öffnet in neuem Tab)

  AD HOC NEWS · 23.09.2026

• BioMarin Pharmaceutical stock holds near its 52-week low (öffnet in neuem Tab)

  AD HOC NEWS · 22.09.2026

• BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) (öffnet in neuem Tab)

  Seeking Alpha · 21.09.2026

• BioMarin Pharmaceutical stock holds near a $12.38 billion value (öffnet in neuem Tab)

  AD HOC NEWS · 20.09.2026

• What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? (öffnet in neuem Tab)

  Yahoo Finance · 19.09.2026

• BioMarin stock steadies after September 17 close (öffnet in neuem Tab)

  AD HOC NEWS · 18.09.2026

• BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone (öffnet in neuem Tab)

  Yahoo Finance · 18.09.2026

• What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders (öffnet in neuem Tab)

  Simply Wall Street · 17.09.2026

• BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) (öffnet in neuem Tab)

  Kalkine Media · 15.09.2026

• BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts (öffnet in neuem Tab)

  Fierce Pharma · 15.09.2026

• BioMarin's stock target raised to $97 after pos... (öffnet in neuem Tab)

  Pluang · 15.09.2026

• Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com (öffnet in neuem Tab)

  Investing.com India · 14.09.2026

• BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board (öffnet in neuem Tab)

  citybiz.co · 14.09.2026

• BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (öffnet in neuem Tab)

  PR Newswire · 14.09.2026

• BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board (öffnet in neuem Tab)

  TradingView · 14.09.2026